secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001104659-24-086114
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio: buntanetap + GLP-1 agonist shows synergistic cognitive boost in AD mouse model
--------------------------------------------------------------------------------

- Combination of buntanetap and dulaglutide (Trulicity) restored cognitive function beyond healthy controls in Alzheimer's mouse model.
- Buntanetap alone restored to 100%, dulaglutide alone to 80%; combination showed 6-10x increase in efficacy.
- GLP-1 agonist dulaglutide was chosen for its good blood-brain barrier permeability among single-chain peptides.
- CEO Maria Maccecchini noted synergy could enhance treatment outcomes while minimizing side effects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924086114/0001104659-24-086114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924086114/tm2420928d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-086114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer